Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Symbol: QNTM (NASDAQ)
Company Description:
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
- Today's Open: $23.5
- Today's High: $25.8
- Today's Low: $22.5
- Today's Volume: 204.93K
- Yesterday Close: $23.83
- Yesterday High: $24.2481
- Yesterday Low: $21.625
- Yesterday Volume: 133.83K
- Last Min Volume: 1
- Last Min High: $24.605
- Last Min Low: $24.605
- Last Min VWAP: $24.605
- Name: Quantum Biopharma Ltd. Class B Subordinate Voting Shares
- Website: https://www.quantumbiopharma.com
- Listed Date: 2018-06-07
- Location: ,
- Market Status: Active
- CIK Number: 0001771885
- SIC Code:
- SIC description:
- Market Cap: $81.56M
- Round Lot: 100
- Outstanding Shares: 3.42M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-07-22 | 6-K | View |
2025-07-18 | SCHEDULE 13G/A | View |
2025-07-10 | SCHEDULE 13G/A | View |
2025-07-10 | SCHEDULE 13G/A | View |
2025-07-10 | SCHEDULE 13G/A | View |
2025-07-08 | 6-K | View |
2025-06-30 | SCHEDULE 13G/A | View |
2025-06-27 | 6-K | View |
2025-06-26 | 6-K | View |
2025-06-23 | SCHEDULE 13D/A | View |
2025-06-23 | SCHEDULE 13D/A | View |
2025-06-17 | 6-K | View |
2025-06-16 | SCHEDULE 13D/A | View |
2025-06-16 | 6-K/A | View |
2025-06-13 | 6-K | View |
2025-06-12 | SCHEDULE 13D | View |
2025-06-11 | SCHEDULE 13G | View |
2025-06-10 | 6-K | View |
2025-06-03 | 6-K | View |
2025-05-30 | 6-K | View |